Senti Biosciences is trading 10.4% down now at $0.40 after second-quarter adjusted EPS of -$0.42 missed the -$0.26 estimate.
- The company reported a $12.75 million quarterly net loss in results released August 14, 2026.
- Cash fell to $6.5 million by June 30, and management indicated funding may not support operations beyond Q4 2026.
- Shares are declining despite elevated volume.